NEOGENOMICS INC NEO
NeoGenomics, Inc., a Nevada corporation (referred to individually as the "Company" or collectively with its subsidiaries as "NeoGenomics," "we," "us," or "our" in this Annual Report on Form 10-K) is the registrant for SEC reporting purposes. Our common stock is listed on The Nasdaq Stock Market LLC ("Nasdaq") under the symbol "NEO."
NeoGenomics provides a wide range of oncology diagnostic testing and consultative services including technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts who specialize in pathology and oncology. We operate a network of cancer-focused testing laboratories in the United States and the United Kingdom. Our mission is to save lives by improving patient care. Our vision is to become the world's leader in cancer testing, information, and decision support by providing uncompromising quality, exceptional service, and innovative solutions.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $727.3M | $660.6M | $591.6M | $509.7M | $484.3M | $444.4M | $408.8M | $276.7M | $240.3M | $231.8M |
| Cost of revenue | $413.0M | $370.5M | $347.0M | $321.8M | $297.3M | $258.6M | $212.0M | $149.5M | $138.3M | $133.7M |
| Gross profit | $314.3M | $290.1M | $244.6M | $187.9M | $187.1M | $185.9M | $196.8M | $127.3M | $102.0M | $98.1M |
| R&D | $37.1M | $31.2M | $27.3M | $30.3M | $21.9M | $8.2M | $8.5M | $3.0M | $3.6M | $4.6M |
| SG&A | $273.3M | $259.7M | $243.1M | $243.4M | $221.3M | $143.8M | $128.0M | $84.8M | $70.4M | $63.9M |
| Total operating expenses | $430.2M | $382.2M | $352.3M | $345.5M | $305.8M | $199.9M | $183.8M | $117.2M | $99.1M | $95.9M |
| Operating income | -$115.9M | -$92.1M | -$107.7M | -$157.6M | -$118.8M | -$14.0M | $13.0M | $10.0M | $2.9M | $2.2M |
| Interest expense | $3.8M | $6.6M | $6.9M | $7.6M | $8.2M | $7.0M | $3.7M | $6.2M | $5.5M | $10.0M |
| Pre-tax income | -$110.3M | -$80.7M | -$97.1M | -$159.3M | -$15.1M | -$14.1M | $3.6M | $3.8M | -$2.6M | -$7.8M |
| Income tax | $2.2M | $1.9M | $9.1M | $15.1M | $6.7M | $18.2M | $4.4M | $1.2M | $2.3M | $1.7M |
| Net income | -$108.0M | -$79.0M | -$88.0M | -$144.0M | -$8.0M | $4.2M | $8.0M | $2.6M | -$396.0K | -$6.1M |
| Shares, diluted (wtd. avg.) | 128.1M | 126.7M | 125.5M | 124.2M | 120.0M | 111.8M | 103.6M | 91.6M | 79.4M | 77.5M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $159.6M | $367.0M | $342.5M | $263.2M | $316.8M | $250.6M | $173.0M | $9.8M | $12.8M | $12.5M |
| Short-term investments | — | — | — | — | $198.6M | $67.5M | $0 | — | — | — |
| Receivables | $159.2M | $150.5M | $131.2M | $119.7M | $112.1M | $106.8M | $94.2M | $76.9M | $60.4M | $55.5M |
| Inventory | $28.6M | $26.7M | $24.2M | $24.3M | $23.4M | $29.5M | $14.4M | $8.7M | $7.5M | $6.3M |
| Total current assets | $376.3M | $596.0M | $596.8M | $605.3M | $681.5M | $448.7M | $290.7M | $103.7M | $85.9M | $78.8M |
| Property, plant and equipment | $84.8M | $94.1M | $92.0M | $102.5M | $109.5M | $85.9M | $64.2M | $60.9M | $36.5M | $34.0M |
| Goodwill | $524.3M | $522.8M | $522.8M | $522.8M | $527.1M | $211.1M | $198.6M | $197.9M | $147.0M | $147.0M |
| Other intangibles | $286.5M | $339.7M | $373.1M | $408.3M | $442.3M | $120.7M | $126.6M | $140.0M | $74.2M | $77.1M |
| Total assets | $1.36B | $1.64B | $1.68B | $1.74B | $1.87B | $988.3M | $709.5M | $505.0M | $344.5M | $337.1M |
| Accounts payable | $23.1M | $21.6M | $20.3M | $20.5M | $17.9M | $25.0M | $19.6M | $17.8M | $10.4M | $16.8M |
| Short-term debt | $0 | $200.8M | — | — | — | $0 | $5.0M | $7.9M | $3.8M | $3.8M |
| Total current liabilities | $88.3M | $301.2M | $96.3M | $89.9M | $87.2M | $73.2M | $63.9M | $60.9M | $36.5M | $38.1M |
| Long-term debt | $341.9M | $340.3M | $538.2M | — | — | — | — | $92.9M | $91.1M | $91.9M |
| Total liabilities | $523.3M | $735.7M | $739.7M | $742.0M | $761.5M | $294.0M | $202.1M | $184.6M | $139.9M | $150.5M |
| Retained earnings | -$433.8M | -$325.8M | -$247.1M | -$159.1M | -$14.8M | -$7.2M | -$11.4M | -$19.4M | -$58.4M | -$52.5M |
| Total equity | $836.6M | $902.3M | $941.5M | $998.0M | $1.11B | $694.3M | $507.4M | $320.4M | $172.0M | $162.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $5.2M | $7.0M | -$2.0M | -$66.0M | -$26.7M | $1.5M | $23.4M | $44.8M | $18.0M | $21.5M |
| Depreciation and amortisation | $36.1M | $39.1M | $37.5M | $35.4M | $30.2M | $25.9M | $20.3M | $15.8M | $15.6M | $15.9M |
| Stock-based compensation | $41.3M | $33.4M | $24.6M | $24.7M | $22.5M | $10.2M | $10.0M | $7.0M | $6.4M | $5.4M |
| Capital expenditure | $27.0M | $41.1M | $28.8M | $30.9M | $64.1M | $29.1M | $20.0M | $14.3M | $13.7M | $7.5M |
| Investing cash flow | -$12.3M | $12.9M | $76.7M | $517.0K | -$632.4M | -$159.4M | -$19.6M | -$139.7M | -$13.7M | -$6.5M |
| Financing cash flow | -$200.3M | $4.6M | $4.6M | $11.8M | $725.3M | $235.6M | $159.5M | $92.0M | -$4.1M | -$25.9M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001077183-26-000014.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $231.8M | $240.3M | $276.7M | $408.8M | $444.4M | $484.3M | $509.7M | $591.6M | $660.6M | $727.3M |
| Gross profit | $98.1M | $102.0M | $127.3M | $196.8M | $185.9M | $187.1M | $187.9M | $244.6M | $290.1M | $314.3M |
| Net income | -$6.1M | -$396.0K | $2.6M | $8.0M | $4.2M | -$8.0M | -$144.0M | -$88.0M | -$79.0M | -$108.0M |
Recent filings and events
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Officer or director change Item 5.02
- Regulation FD disclosure Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 8734
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| ULS | UL Solutions Inc. | $14.83B | 45.9x | 6.4% |
| AIDX | 20/20 Biolabs, Inc. | $3.0M | — | 16.7% |